Company / Cash & Equivalents
IMMUCELL CORP /DE/ Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.8M
FY2025
5-year range
$978.7K / $5.2M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +289% YoY in FY2025, a notable deviation from the 8-year average annual change of +87%.
Based on SEC 10-K filings.
$4M in FY2025 with a 10-year CAGR of +16.2%.
Declined from $5M to $4M over the past 8 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +16.2%
Key checks
Key Insights
- Peak cash & equivalents was recorded in FY2017.
- Lowest cash & equivalents in the period was in FY2013.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.8M | - |
| FY2024 | - | - |
| FY2023 | $978.7K | -81.0% |
| FY2017 | $5.2M | +227.4% |
| FY2016 | $1.6M | +85.1% |
| FY2015 | $850.0K | -68.2% |
| FY2014 | $2.7M | +242.1% |
| FY2013 | $781.5K | -44.1% |
| FY2012 | $1.4M | +43.4% |
| FY2011 | $975.5K | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026